Platelet-rich plasma (PRP) for jumper?s knee
Not Applicable
Completed
- Conditions
- Patellar tendinopathy (jumper's knee)Musculoskeletal Diseases
- Registration Number
- ISRCTN01626109
- Lead Sponsor
- Biomet Europe B.V. (Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
1. Jumper?s knee patients aged 18-55
2. Pain at the inferior pole of the patella for more than 3 months
3. Tendinosis or thickening compared to the contralateral side of > 3mm, detected with ultrasonography or MRI
4. Already undergone eccentric training for 6 weeks following a standardized protocol
Exclusion Criteria
1. Pregnancy
2. Injection in the patellar tendon in the last 3 months, irrespective of the applied substance
3. Operation on the patellar tendon in the past
4. At examination indications for intra articular pathology or patellofemoral pain syndrome
5. Chronic NSAID use in the last 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method VISA-P ? a validated questionnaire for patellar tendinopathy which assesses pain and function of the knee (100 = maximal score, indicating a normal functional knee, 0 = minimal score). <br>This will be assessed at baseline, 6, 12, 26 and 52 weeks after injection treatment.
- Secondary Outcome Measures
Name Time Method 1. Ultrasound abnormalities (tendinosis zone, thickness of tendon and degree of neovascularisation) at baseline and 12 weeks after injection<br>2. Pain, measured using Visual Analogue Scale (VAS) score (0 = no pain, 10 = unbearable pain) <br>3. Costs of the treatments<br>4. Return to sport (level and duration)